tetano
Editor, Senior Moderator
EBioMedicine. 2018 Jan 10. pii: S2352-3964(18)30007-0. doi: 10.1016/j.ebiom.2018.01.007. [Epub ahead of print]
[h=1]Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).[/h] Tackenberg B[SUP]1[/SUP], Schneider M[SUP]2[/SUP], Blaes F[SUP]3[/SUP], Eienbr?ker C[SUP]2[/SUP], Schade-Brittinger C[SUP]4[/SUP], Wellek A[SUP]2[/SUP], Deschauer M[SUP]5[/SUP], Eickmann M[SUP]6[/SUP], Klenk HD[SUP]6[/SUP], M?ller HH[SUP]7[/SUP], Sommer N[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] It is a continuous matter of discussion whether immune activation by vaccination in general and Influenza vaccination in particular increases the risk for clinical deterioration of autoimmune diseases. This prospective study investigated the serological and clinical course of autoimmune Myasthenia gravis (MG) after a seasonal influenza vaccination.
[h=4]METHODS:[/h] This randomized, placebo-controlled, double-blind study enrolled MG patients with antibodies against acetylcholine-receptors (AChR-ab). They were allocated to receive seasonal influenza vaccine or placebo. The primary endpoint was the relative change of AChR-ab-titer over 12weeks. A relative increase of 20% was set as non-inferiority margin. Secondary endpoints were clinical changes in the modified Quantitative Myasthenia Gravis Score (QMG), increase of anti-influenza-ELISA-antibodies, and changes of treatment. The study is registered with Clinicaltrialsregister.eu, EudraCT number 2006-004374-27.
[h=4]FINDINGS:[/h] 62 patients were included. Mean?standard deviation (median) in the vaccine and placebo group were AChR-ab-titer changes of -6.0%?23.3% (-4.0%) and -2.8%?22.0% (-0.5%) and QMG score changes of -0.08?0.27 (0.17) and 0.11?0.31 (0.00), respectively. The difference between groups (Hodges-Lehmann estimate with 95% CI) was - for the AChR-ab-titer change 4?0% [-13.3%, 4.5%] (p=0.28 for testing a difference, p<0.0001 for testing non-inferiority) and for the QMG change 0?00 [-0.17, 0.00] (p=0.79 for testing a difference). The occurrence of 74 adverse events (AE) was comparable between groups. The most common AE was flu-like symptoms. One serious AE (hospitalisation following gastrointestinal haemorrhage) in the verum group was not related to the vaccine.
[h=4]INTERPRETATION:[/h] Influenza vaccination in MG is safe. Uprating the potential risk of a severe course of MG exacerbation during influenza infection compared to the 95% CI differences for the endpoints, vaccination is principally indicated in this patient population.
Copyright ? 2018 The Authors. Published by Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Acetylcholine receptor antibody titer; Autoimmune myasthenia gravis; QMG score; Randomized controlled trial; Vaccination
PMID: 29337134 DOI: 10.1016/j.ebiom.2018.01.007
Free full text
[h=1]Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).[/h] Tackenberg B[SUP]1[/SUP], Schneider M[SUP]2[/SUP], Blaes F[SUP]3[/SUP], Eienbr?ker C[SUP]2[/SUP], Schade-Brittinger C[SUP]4[/SUP], Wellek A[SUP]2[/SUP], Deschauer M[SUP]5[/SUP], Eickmann M[SUP]6[/SUP], Klenk HD[SUP]6[/SUP], M?ller HH[SUP]7[/SUP], Sommer N[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] It is a continuous matter of discussion whether immune activation by vaccination in general and Influenza vaccination in particular increases the risk for clinical deterioration of autoimmune diseases. This prospective study investigated the serological and clinical course of autoimmune Myasthenia gravis (MG) after a seasonal influenza vaccination.
[h=4]METHODS:[/h] This randomized, placebo-controlled, double-blind study enrolled MG patients with antibodies against acetylcholine-receptors (AChR-ab). They were allocated to receive seasonal influenza vaccine or placebo. The primary endpoint was the relative change of AChR-ab-titer over 12weeks. A relative increase of 20% was set as non-inferiority margin. Secondary endpoints were clinical changes in the modified Quantitative Myasthenia Gravis Score (QMG), increase of anti-influenza-ELISA-antibodies, and changes of treatment. The study is registered with Clinicaltrialsregister.eu, EudraCT number 2006-004374-27.
[h=4]FINDINGS:[/h] 62 patients were included. Mean?standard deviation (median) in the vaccine and placebo group were AChR-ab-titer changes of -6.0%?23.3% (-4.0%) and -2.8%?22.0% (-0.5%) and QMG score changes of -0.08?0.27 (0.17) and 0.11?0.31 (0.00), respectively. The difference between groups (Hodges-Lehmann estimate with 95% CI) was - for the AChR-ab-titer change 4?0% [-13.3%, 4.5%] (p=0.28 for testing a difference, p<0.0001 for testing non-inferiority) and for the QMG change 0?00 [-0.17, 0.00] (p=0.79 for testing a difference). The occurrence of 74 adverse events (AE) was comparable between groups. The most common AE was flu-like symptoms. One serious AE (hospitalisation following gastrointestinal haemorrhage) in the verum group was not related to the vaccine.
[h=4]INTERPRETATION:[/h] Influenza vaccination in MG is safe. Uprating the potential risk of a severe course of MG exacerbation during influenza infection compared to the 95% CI differences for the endpoints, vaccination is principally indicated in this patient population.
Copyright ? 2018 The Authors. Published by Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Acetylcholine receptor antibody titer; Autoimmune myasthenia gravis; QMG score; Randomized controlled trial; Vaccination
PMID: 29337134 DOI: 10.1016/j.ebiom.2018.01.007
Free full text